PMV Pharmaceuticals Inc., a company developing cancer therapies to restore p53, a protein commonly mutated in tumors, has landed a $74 million series B financing. Topspin Biotech Fund and Euclidean ...
PRINCETON, N.J., Jan. 05, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic ...
PRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic ...
DOYLESTOWN, Pa. & PRINCETON, N.J.--(BUSINESS WIRE)--PMV Pharmaceuticals, Inc., and Chiromics LLC today announced that they have entered into a collaboration whereby PMV Pharma has a non-exclusive ...
David Mack Ph.D., PMV Pharma’s CEO and Co-founder, said, “I would like to thank Leila and Winston for their dedicated and unwavering support of PMV, and we wish them both well in their future ...
PC14586 clinical program to be led by Deepika Jalota, Pharm.D. (Chief Development Officer) and Marc Fellous, M.D. (Senior Vice President, Head of Clinical Development and Medical Affairs) Michael ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results